Comparative Pharmacology
Head-to-head clinical analysis: CLORPRES versus DEMI REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORPRES versus DEMI REGROTON.
CLORPRES vs DEMI-REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination